ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Boston-based Intarcia Therapeutics has signed up France’s Servier as a partner to develop the diabetes treatment ITCA 650 outside the U.S. and Japan. ITCA 650 is a matchstick-sized implant that delivers exenatide, a peptide that is the active ingredient in the diabetes drug Byetta. Intarcia, which calls itself the highest-valued private biotech company in history, will get $171 million up front and three early-stage regulatory milestones totaling $230 million. ITCA 650 is now in Phase III clinical trials for the treatment of type 2 diabetes.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X